J E Geddings1, Y Hisada2, Y Boulaftali2, T M Getz2, M Whelihan2,3, R Fuentes1, R Dee1, B C Cooley1, N S Key1,2,3, A S Wolberg1, W Bergmeier4, N Mackman1,2,3. 1. Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC, USA. 2. Division of Hematology/Oncology, Thrombosis and Hemostasis Program, UNC McAllister Heart Institute, University of North Carolina, Chapel Hill, NC, USA. 3. Department of Medicine, University of North Carolina, Chapel Hill, NC, USA. 4. Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC, USA.
Abstract
UNLABELLED: ESSENTIALS: Cancer patients have a high rate of venous thrombosis (VT) but the underlying mechanisms are unknown. Tumor-derived, tissue factor-positive microvesicles in platelet activation in vitro and in vivo were studied. Tumor-derived, tissue factor-positive microvesicles enhanced VT in mice. Platelets may contribute to VT in some cancer patients, and this could be prevented with antiplatelet drugs. BACKGROUND: Cancer patients have an approximately 4-fold increased risk of venous thromboembolism (VTE) compared with the general population, and cancer patients with VTE have reduced survival. Tumor cells constitutively release small membrane vesicles called microvesicles (MVs) that may contribute to thrombosis in cancer patients. Clinical studies have shown that levels of circulating tumor-derived, tissue factor-positive (TF(+) ) MVs in pancreatic cancer patients are associated with VTE. Objectives We tested the hypothesis that TF(+) tumor-derived MVs (TMVs) activate platelets in vitro and in mice. MATERIALS AND METHODS: We selected two human pancreatic adenocarcinoma cell lines expressing high (BxPc-3) and low (L3.6pl) levels of TF as models to study the effect of TF(+) TMVs on platelets and thrombosis. RESULTS AND CONCLUSIONS: We found that both types of TF(+) TMVs activated human platelets and induced aggregation in vitro in a TF and thrombin-dependent manner. Further, injection of BxPc-3 TF(+) TMVs triggered platelet activation in vivo and enhanced thrombosis in two mouse models of venous thrombosis in a TF-dependent manner. Importantly, BxPc-3 TF(+) TMV-enhanced thrombosis was reduced in Par4-deficient mice and in wild-type mice treated with clopidogrel, suggesting that platelet activation was required for enhanced thrombosis. These studies suggest that TF(+) TMV-induced platelet activation contributes to thrombosis in cancer patients.
UNLABELLED: ESSENTIALS: Cancerpatients have a high rate of venous thrombosis (VT) but the underlying mechanisms are unknown. Tumor-derived, tissue factor-positive microvesicles in platelet activation in vitro and in vivo were studied. Tumor-derived, tissue factor-positive microvesicles enhanced VT in mice. Platelets may contribute to VT in some cancerpatients, and this could be prevented with antiplatelet drugs. BACKGROUND:Cancerpatients have an approximately 4-fold increased risk of venous thromboembolism (VTE) compared with the general population, and cancerpatients with VTE have reduced survival. Tumor cells constitutively release small membrane vesicles called microvesicles (MVs) that may contribute to thrombosis in cancerpatients. Clinical studies have shown that levels of circulating tumor-derived, tissue factor-positive (TF(+) ) MVs in pancreatic cancerpatients are associated with VTE. Objectives We tested the hypothesis that TF(+) tumor-derived MVs (TMVs) activate platelets in vitro and in mice. MATERIALS AND METHODS: We selected two humanpancreatic adenocarcinoma cell lines expressing high (BxPc-3) and low (L3.6pl) levels of TF as models to study the effect of TF(+) TMVs on platelets and thrombosis. RESULTS AND CONCLUSIONS: We found that both types of TF(+) TMVs activated human platelets and induced aggregation in vitro in a TF and thrombin-dependent manner. Further, injection of BxPc-3 TF(+) TMVs triggered platelet activation in vivo and enhanced thrombosis in two mouse models of venous thrombosis in a TF-dependent manner. Importantly, BxPc-3 TF(+) TMV-enhanced thrombosis was reduced in Par4-deficient mice and in wild-type mice treated with clopidogrel, suggesting that platelet activation was required for enhanced thrombosis. These studies suggest that TF(+) TMV-induced platelet activation contributes to thrombosis in cancerpatients.
Authors: Russell D Hull; Graham F Pineo; Rollin F Brant; Andrew F Mah; Natasha Burke; Richard Dear; Turnly Wong; Roy Cook; Susan Solymoss; Man-Chiu Poon; Gary Raskob Journal: Am J Med Date: 2006-12 Impact factor: 4.965
Authors: M E T Tesselaar; F P H T M Romijn; I K Van Der Linden; F A Prins; R M Bertina; S Osanto Journal: J Thromb Haemost Date: 2006-12-13 Impact factor: 5.824
Authors: Arunima Ghosh; Wei Li; Maria Febbraio; Ricardo G Espinola; Keith R McCrae; Erin Cockrell; Roy L Silverstein Journal: J Clin Invest Date: 2008-05 Impact factor: 14.808
Authors: J W Blom; J P M Vanderschoot; M J Oostindiër; S Osanto; F J M van der Meer; F R Rosendaal Journal: J Thromb Haemost Date: 2006-03 Impact factor: 5.824
Authors: Alok A Khorana; Steven A Ahrendt; Charlotte K Ryan; Charles W Francis; Ralph H Hruban; Ying Chuan Hu; Galen Hostetter; Jennifer Harvey; Mark B Taubman Journal: Clin Cancer Res Date: 2007-05-15 Impact factor: 12.531
Authors: Vinita Yadav; Liguo Chi; Raymond Zhao; Benjamin E Tourdot; Srilakshmi Yalavarthi; Benjamin N Jacobs; Alison Banka; Hui Liao; Sharon Koonse; Anuli C Anyanwu; Scott H Visovatti; Michael A Holinstat; J Michelle Kahlenberg; Jason S Knight; David J Pinsky; Yogendra Kanthi Journal: J Clin Invest Date: 2019-04-16 Impact factor: 14.808
Authors: Camille Faes; Anton Ilich; Amandine Sotiaux; Erica M Sparkenbaugh; Michael W Henderson; Laura Buczek; Joan D Beckman; Patrick Ellsworth; Denis F Noubouossie; Lantarima Bhoopat; Mark Piegore; Céline Renoux; Wolfgang Bergmeier; Yara Park; Kenneth I Ataga; Brian Cooley; Alisa S Wolberg; Nigel S Key; Rafal Pawlinski Journal: Blood Date: 2019-04-05 Impact factor: 22.113